Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Expression of antibody–drug conjugate targets in soft tissue sarcomas
François Bertucci, Pascal Finetti, Lénaïg Mescam, Audrey Monneur, A Frejafon, Axel Le Cesne, Isabelle Treilleux, Antoîne Italiano, M. Brahmi, Jean Yves Blay, Émilie Mamessier (2025). Expression of antibody–drug conjugate targets in soft tissue sarcomas. , 10(10), DOI: https://doi.org/10.1016/j.esmoop.2025.105837.
Article33 days agoLong-term clinical outcome assessments in patients with tenosynovial giant cell tumor treated with vimseltinib: 1-year results from the MOTION phase 3 trial.
Vivek A. Bhadri, Hans Gelderblom, Silvia Stacchiotti, Sebastian Bauer, Andrew J. Wagner, Michiel A. J. van de Sande, Nicholas M. Bernthal, Antonio López–Pousa, Albiruni Ryan Abdul Razak, Antoîne Italiano, Mahbubl Ahmed, Axel Le Cesne, Christopher Tait, Amanda Saunders, Nicholas Zeringo, B. Harrow, Maitreyi G. Sharma, Matthew L. Sherman, Jean Yves Blay, William D. Tap (2025). Long-term clinical outcome assessments in patients with tenosynovial giant cell tumor treated with vimseltinib: 1-year results from the MOTION phase 3 trial.. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.11558.
Article33 days agoBroad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trial
Olivier Trédan, Damien Pouessel, Nicolas Penel, Sylvie Chabaud, Carlos Gomez‐Roca, Jean-Pierre Delord, Diane Pannier, Mehdi Brahmi, Michel Fabbro, Marie-Eve Garcia, Delphine Larrieu‐Ciron, Isabelle Ray‐Coquard, Marie Viala, Antoîne Italiano, Diégo Tosi, Philippe A. Cassier, Armelle Dufresne, Valéry Attignon, Sandrine Boyault, Isabelle Treilleux, Alain Viari, David Pérol, Jean Yves Blay (2025). Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trial. , 31(5), DOI: https://doi.org/10.1038/s41591-025-03613-x.
Article33 days agoClinical presentation, management and outcome of 11132 patients with liposarcoma: a population-based study from the NETSARC+ registry
Jean Yves Blay, Maud Toulmonde, Thibaud Valentin, Nelly Firmin, Sarah Watson, Florence Duffaud, Emmanuelle Bompas, María Rios, M. Ropars, Philippe Anract, Armelle Dufresne, Justine Gantzer, Louis‐Romée Le Nail, Esma Saâda, Alice Hervieu, François Bertucci, Pascale Dubray‐Longeras, Vincent Crenn, Christophe Perrin, Pauline Soibinet, B. Verret, Antoîne Italiano, Gauthier Decanter, Gwénaël Ferron, Sébastien Carrère, Sylvie Bonvalot, Mehdi Brahmi, Clémence Hénon, Mariella Spalato Ceruso, Loïc Lebellec, Anne Ducassou, Julien Colard‐Thomas, Sophie Piperno‐Neumann, Jean Camille Mattei, F. Gouin, M. Faron, Thomas Ryckewaert, Pierre Méeus, Charles Honoré, François Le Loarer, J.M. Coindre, Carine Ngo, Alexandra Meurgey, Marie Karanian, Claire Chemin-Airiau, Françoise Ducimetière, Magali Morelle, Nicolas Penel, Axel Le Cesne (2025). Clinical presentation, management and outcome of 11132 patients with liposarcoma: a population-based study from the NETSARC+ registry. , 57, DOI: https://doi.org/10.1016/j.lanepe.2025.101403.
Article33 days agoImatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial
Desmond Yip, John Zalcberg, Jean Yves Blay, Mikael Eriksson, David Espinoza, Timothy Price, Sandrine Marréaud, Antoîne Italiano, Neeltje Steeghs, Kjetil Boye, Craig Underhill, Val Gebski, John Simes, Hans Gelderblom, Heikki Joensuu (2025). Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial. , 132(10), DOI: https://doi.org/10.1038/s41416-025-02983-w.
Article33 days ago